{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:59:58Z","timestamp":1793699998877,"version":"4.5.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["P01 DA028555"],"award-info":[{"award-number":["P01 DA028555"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["P01 DA028555-09S1"],"award-info":[{"award-number":["P01 DA028555-09S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["R01 NS36126"],"award-info":[{"award-number":["R01 NS36126"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["R01 MH121402"],"award-info":[{"award-number":["R01 MH121402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["P30 MH062261"],"award-info":[{"award-number":["P30 MH062261"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["R01 MH115860"],"award-info":[{"award-number":["R01 MH115860"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["2R01 NS034239"],"award-info":[{"award-number":["2R01 NS034239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["R01 AI158160"],"award-info":[{"award-number":["R01 AI158160"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["R01AI145542"],"award-info":[{"award-number":["R01AI145542"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"bioimaging core (mri) grant from the nebraska center for nanomedicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dolutegravir (DTG) is a first-line antiretroviral drug (ARV) used in combination therapy for the treatment of human immunodeficiency virus type-1 (HIV-1) infection. The drug is effective, safe, and well tolerated. Nonetheless, concerns have recently emerged for its usage in pregnant women or those of child-bearing age. Notably, DTG-based ARV regimens have been linked to birth defects seen as a consequence of periconceptional usages. To this end, uncovering an underlying mechanism for DTG-associated adverse fetal development outcomes has gained clinical and basic research interest. We now report that DTG inhibits matrix metalloproteinases (MMPs) activities that could affect fetal neurodevelopment. DTG is a broad-spectrum MMPs inhibitor and binds to Zn<jats:sup>++<\/jats:sup> at the enzyme\u2019s catalytic domain. Studies performed in pregnant mice show that DTG readily reaches the fetal central nervous system during gestation and inhibits MMP activity. Postnatal screenings of brain health in mice pups identified neuroinflammation and neuronal impairment. These abnormalities persist as a consequence of in utero DTG exposure. We conclude that DTG inhibition of MMPs activities during gestation has the potential to affect prenatal and postnatal neurodevelopment.<\/jats:p>","DOI":"10.1007\/s12035-021-02508-5","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T08:03:01Z","timestamp":1628928181000},"page":"5703-5721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-4461","authenticated-orcid":false,"given":"Aditya N.","family":"Bade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoEllyn M.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson J.","family":"Edagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-0370","authenticated-orcid":false,"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"2508_CR1","unstructured":"World Health Organization (2016) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach\u2014second edition. https:\/\/www.who.int\/hiv\/pub\/arv\/chapter4.pdf?ua=1. Accessed February 27 2021"},{"issue":"9","key":"2508_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1097\/QAD.0000000000002550","volume":"34","author":"CS Crowell","year":"2020","unstructured":"Crowell CS, Williams PL, Yildirim C, Van Dyke RB, Smith R, Chadwick EG, Seage GR 3rd, Diperna A, Hazra R, Pediatric HIVACS (2020) Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected. AIDS 34(9):1377\u20131387. https:\/\/doi.org\/10.1097\/QAD.0000000000002550","journal-title":"AIDS"},{"key":"2508_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4479","volume":"366","author":"V Ramokolo","year":"2019","unstructured":"Ramokolo V, Goga AE, Slogrove AL, Powis KM (2019) Unmasking the vulnerabilities of uninfected children exposed to HIV. BMJ 366:l4479. https:\/\/doi.org\/10.1136\/bmj.l4479","journal-title":"BMJ"},{"issue":"6","key":"2508_CR4","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/S1473-3099(16)00055-4","volume":"16","author":"C Evans","year":"2016","unstructured":"Evans C, Jones CE, Prendergast AJ (2016) HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. Lancet Infect Dis 16(6):e92\u2013e107. https:\/\/doi.org\/10.1016\/S1473-3099(16)00055-4","journal-title":"Lancet Infect Dis"},{"key":"2508_CR5","unstructured":"Department of Health and Human Services (DHHS), Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. Accessed June 11 2021"},{"key":"2508_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","volume":"239","author":"BG Brenner","year":"2017","unstructured":"Brenner BG, Wainberg MA (2017) Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res 239:1\u20139. https:\/\/doi.org\/10.1016\/j.virusres.2016.07.006","journal-title":"Virus Res"},{"key":"2508_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30093-6","author":"J Dorward","year":"2018","unstructured":"Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, Abdool Karim SS, Garrett N (2018) Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. https:\/\/doi.org\/10.1016\/S2352-3018(18)30093-6","journal-title":"Lancet HIV"},{"issue":"2","key":"2508_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S2055-6640(20)30247-8","volume":"4","author":"A Hill","year":"2018","unstructured":"Hill A, Clayden P, Thorne C, Christie R, Zash R (2018) Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review. J Virus Erad 4(2):66\u201371","journal-title":"J Virus Erad"},{"issue":"10","key":"2508_CR9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1056\/NEJMc1807653","volume":"379","author":"R Zash","year":"2018","unstructured":"Zash R, Makhema J, Shapiro RL (2018) Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 379(10):979\u2013981. https:\/\/doi.org\/10.1056\/NEJMc1807653","journal-title":"N Engl J Med"},{"issue":"9","key":"2508_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","volume":"381","author":"R Zash","year":"2019","unstructured":"Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, Isaacson A, Davey S, Mabuta J, Mmalane M, Gaolathe T, Essex M, Lockman S, Makhema J, Shapiro RL (2019) Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med 381(9):827\u2013840. https:\/\/doi.org\/10.1056\/NEJMoa1905230","journal-title":"N Engl J Med"},{"key":"2508_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103167","volume":"63","author":"H Mohan","year":"2020","unstructured":"Mohan H, Lenis MG, Laurette EY, Tejada O, Sanghvi T, Leung KY, Cahill LS, Sled JG, Delgado-Olguin P, Greene NDE, Copp AJ, Serghides L (2020) Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels. EBioMedicine 63:103167. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103167","journal-title":"EBioMedicine"},{"key":"2508_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-019-09880-z","author":"JG Schnoll","year":"2019","unstructured":"Schnoll JG, Temsamrit B, Zhang D, Song H, Ming GL, Christian KM (2019) Evaluating neurodevelopmental consequences of perinatal exposure to antiretroviral drugs: current challenges and new approaches. J Neuroimmune Pharmacol. https:\/\/doi.org\/10.1007\/s11481-019-09880-z","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"2508_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11904-019-00459-0","volume":"16","author":"CJ Wedderburn","year":"2019","unstructured":"Wedderburn CJ, Evans C, Yeung S, Gibb DM, Donald KA, Prendergast AJ (2019) Growth and neurodevelopment of HIV-exposed uninfected children: a conceptual framework. Curr HIV\/AIDS Rep 16(6):501\u2013513. https:\/\/doi.org\/10.1007\/s11904-019-00459-0","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2508_CR14","doi-asserted-by":"publisher","unstructured":"Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR, Jr, Hughes SH (2021) Integrase strand transfer inhibitors are effective anti-HIV drugs. Viruses 13 (2). https:\/\/doi.org\/10.3390\/v13020205","DOI":"10.3390\/v13020205"},{"issue":"1","key":"2508_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semcdb.2007.06.003","volume":"19","author":"SM Agrawal","year":"2008","unstructured":"Agrawal SM, Lau L, Yong VW (2008) MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 19(1):42\u201351. https:\/\/doi.org\/10.1016\/j.semcdb.2007.06.003","journal-title":"Semin Cell Dev Biol"},{"key":"2508_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pneurobio.2016.08.002","volume":"155","author":"ME De Stefano","year":"2017","unstructured":"De Stefano ME, Herrero MT (2017) The multifaceted role of metalloproteinases in physiological and pathological conditions in embryonic and adult brains. Prog Neurobiol 155:36\u201356. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.08.002","journal-title":"Prog Neurobiol"},{"issue":"13","key":"2508_CR17","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1002\/jnr.21273","volume":"85","author":"IM Ethell","year":"2007","unstructured":"Ethell IM, Ethell DW (2007) Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 85(13):2813\u20132823. https:\/\/doi.org\/10.1002\/jnr.21273","journal-title":"J Neurosci Res"},{"key":"2508_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.isci.2019.05.027","volume":"16","author":"H Kanda","year":"2019","unstructured":"Kanda H, Shimamura R, Koizumi-Kitajima M, Okano H (2019) Degradation of extracellular matrix by matrix metalloproteinase 2 is essential for the establishment of the blood-brain barrier in Drosophila. iScience 16:218\u2013229. https:\/\/doi.org\/10.1016\/j.isci.2019.05.027","journal-title":"iScience"},{"issue":"1","key":"2508_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1183\/09031936.00146510","volume":"38","author":"S Loffek","year":"2011","unstructured":"Loffek S, Schilling O, Franzke CW (2011) Series \u201cmatrix metalloproteinases in lung health and disease\u201d: biological role of matrix metalloproteinases: a critical balance. Eur Respir J 38(1):191\u2013208. https:\/\/doi.org\/10.1183\/09031936.00146510","journal-title":"Eur Respir J"},{"issue":"3","key":"2508_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrm2125","volume":"8","author":"A Page-McCaw","year":"2007","unstructured":"Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8(3):221\u2013233. https:\/\/doi.org\/10.1038\/nrm2125","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2508_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fncel.2015.00280","volume":"9","author":"SM Reinhard","year":"2015","unstructured":"Reinhard SM, Razak K, Ethell IM (2015) A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Front Cell Neurosci 9:280. https:\/\/doi.org\/10.3389\/fncel.2015.00280","journal-title":"Front Cell Neurosci"},{"issue":"9","key":"2508_CR22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0271678X16655551","volume":"36","author":"RG Rempe","year":"2016","unstructured":"Rempe RG, Hartz AMS, Bauer B (2016) Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab 36(9):1481\u20131507. https:\/\/doi.org\/10.1177\/0271678X16655551","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"2508_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12861-018-0175-3","volume":"18","author":"N Shinotsuka","year":"2018","unstructured":"Shinotsuka N, Yamaguchi Y, Nakazato K, Matsumoto Y, Mochizuki A, Miura M (2018) Caspases and matrix metalloproteases facilitate collective behavior of non-neural ectoderm after hindbrain neuropore closure. BMC Dev Biol 18(1):17. https:\/\/doi.org\/10.1186\/s12861-018-0175-3","journal-title":"BMC Dev Biol"},{"issue":"3","key":"2508_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4103\/1673-5374.179030","volume":"11","author":"CD Small","year":"2016","unstructured":"Small CD, Crawford BD (2016) Matrix metalloproteinases in neural development: a phylogenetically diverse perspective. Neural Regen Res 11(3):357\u2013362. https:\/\/doi.org\/10.4103\/1673-5374.179030","journal-title":"Neural Regen Res"},{"issue":"2","key":"2508_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/cvr\/cvm102","volume":"78","author":"VW van Hinsbergh","year":"2008","unstructured":"van Hinsbergh VW, Koolwijk P (2008) Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78(2):203\u2013212. https:\/\/doi.org\/10.1093\/cvr\/cvm102","journal-title":"Cardiovasc Res"},{"key":"2508_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/789083","volume":"2012","author":"H Fujioka","year":"2012","unstructured":"Fujioka H, Dairyo Y, Yasunaga K, Emoto K (2012) Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease. Biochem Res Int 2012:789083. https:\/\/doi.org\/10.1155\/2012\/789083","journal-title":"Biochem Res Int"},{"issue":"20","key":"2508_CR27","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/bioinformatics\/btu426","volume":"30","author":"E Krieger","year":"2014","unstructured":"Krieger E, Vriend G (2014) YASARA View\u2014molecular graphics for all devices\u2014from smartphones to workstations. Bioinformatics 30(20):2981\u20132982. https:\/\/doi.org\/10.1093\/bioinformatics\/btu426","journal-title":"Bioinformatics"},{"issue":"1","key":"2508_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","volume":"12","author":"E Harder","year":"2016","unstructured":"Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL, Kaus JW, Cerutti DS, Krilov G, Jorgensen WL, Abel R, Friesner RA (2016) OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 12(1):281\u2013296. https:\/\/doi.org\/10.1021\/acs.jctc.5b00864","journal-title":"J Chem Theory Comput"},{"issue":"1","key":"2508_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41467-018-02885-x","volume":"9","author":"B Sillman","year":"2018","unstructured":"Sillman B, Bade AN, Dash PK, Bhargavan B, Kocher T, Mathews S, Su H, Kanmogne GD, Poluektova LY, Gorantla S, McMillan J, Gautam N, Alnouti Y, Edagwa B, Gendelman HE (2018) Creation of a long-acting nanoformulated dolutegravir. Nat Commun 9(1):443. https:\/\/doi.org\/10.1038\/s41467-018-02885-x","journal-title":"Nat Commun"},{"key":"2508_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1750-1326-9-58","volume":"9","author":"MD Boska","year":"2014","unstructured":"Boska MD, Dash PK, Knibbe J, Epstein AA, Akhter SP, Fields N, High R, Makarov E, Bonasera S, Gelbard HA, Poluektova LY, Gendelman HE, Gorantla S (2014) Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Mol Neurodegener 9:58. https:\/\/doi.org\/10.1186\/1750-1326-9-58","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2508_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/jmri.21999","volume":"31","author":"JP Wijnen","year":"2010","unstructured":"Wijnen JP, van Asten JJ, Klomp DW, Sjobakk TE, Gribbestad IS, Scheenen TW, Heerschap A (2010) Short echo time 1H MRSI of the human brain at 3T with adiabatic slice-selective refocusing pulses; reproducibility and variance in a dual center setting. J Magn Reson Imaging 31(1):61\u201370. https:\/\/doi.org\/10.1002\/jmri.21999","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"2508_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/(sici)1522-2594(199904)41:4<649::aid-mrm2>3.0.co;2-g","volume":"41","author":"I Tkac","year":"1999","unstructured":"Tkac I, Starcuk Z, Choi IY, Gruetter R (1999) In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 41(4):649\u2013656. https:\/\/doi.org\/10.1002\/(sici)1522-2594(199904)41:4%3c649::aid-mrm2%3e3.0.co;2-g","journal-title":"Magn Reson Med"},{"issue":"1","key":"2508_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635","journal-title":"Bioinformatics"},{"key":"2508_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323. https:\/\/doi.org\/10.1186\/1471-2105-12-323","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"2508_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/14756360701511292","volume":"23","author":"XC Cheng","year":"2008","unstructured":"Cheng XC, Fang H, Xu WF (2008) Advances in assays of matrix metalloproteinases (MMPs) and their inhibitors. J Enzyme Inhib Med Chem 23(2):154\u2013167. https:\/\/doi.org\/10.1080\/14756360701511292","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2508_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-4939-7111-4_8","volume":"1626","author":"Z Ren","year":"2017","unstructured":"Ren Z, Chen J, Khalil RA (2017) Zymography as a research tool in the study of matrix metalloproteinase inhibitors. Methods Mol Biol 1626:79\u2013102. https:\/\/doi.org\/10.1007\/978-1-4939-7111-4_8","journal-title":"Methods Mol Biol"},{"issue":"12","key":"2508_CR37","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1161\/ATVBAHA.108.173898","volume":"28","author":"AC Newby","year":"2008","unstructured":"Newby AC (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28(12):2108\u20132114. https:\/\/doi.org\/10.1161\/ATVBAHA.108.173898","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2508_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174853","volume":"12","author":"J Vandooren","year":"2017","unstructured":"Vandooren J, Knoops S, Aldinucci Buzzo JL, Boon L, Martens E, Opdenakker G, Kolaczkowska E (2017) Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: a comparative study. PLoS ONE 12(4):e0174853. https:\/\/doi.org\/10.1371\/journal.pone.0174853","journal-title":"PLoS ONE"},{"issue":"12","key":"2508_CR39","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nrd4390","volume":"13","author":"RE Vandenbroucke","year":"2014","unstructured":"Vandenbroucke RE, Libert C (2014) Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 13(12):904\u2013927. https:\/\/doi.org\/10.1038\/nrd4390","journal-title":"Nat Rev Drug Discov"},{"key":"2508_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1861","author":"L Dickinson","year":"2020","unstructured":"Dickinson L, Walimbwa S, Singh Y, Kaboggoza J, Kintu K, Sihlangu M, Coombs JA, Malaba TR, Byamugisha J, Pertinez H, Amara A, Gini J, Else L, Heiberg C, Hodel EM, Reynolds H, Myer L, Waitt C, Khoo S, Lamorde M, Orrell C (2020) Infant exposure to dolutegravir through placental and breastmilk transfer: a population pharmacokinetic analysis of DolPHIN-1. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1861","journal-title":"Clin Infect Dis"},{"issue":"17","key":"2508_CR41","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1097\/QAD.0000000000001259","volume":"30","author":"R Kobbe","year":"2016","unstructured":"Kobbe R, Schalkwijk S, Dunay G, Eberhard JM, Schulze-Sturm U, Hollwitz B, Degen O, Teulen M, Colbers A, Burger D (2016) Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. AIDS 30(17):2731\u20132733. https:\/\/doi.org\/10.1097\/QAD.0000000000001259","journal-title":"AIDS"},{"issue":"9","key":"2508_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002895","volume":"16","author":"C Waitt","year":"2019","unstructured":"Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, Kaboggoza J, Sihlangu M, Coombs JA, Malaba T, Byamugisha J, Amara A, Gini J, Else L, Heiburg C, Hodel EM, Reynolds H, Mehta U, Byakika-Kibwika P, Hill A, Myer L, Lamorde M, Khoo S (2019) Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study). PLoS Med 16(9):e1002895. https:\/\/doi.org\/10.1371\/journal.pmed.1002895","journal-title":"PLoS Med"},{"issue":"8","key":"2508_CR43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/QAD.0000000000001055","volume":"30","author":"JM Lewis","year":"2016","unstructured":"Lewis JM, Railton E, Riordan A, Khoo S, Chaponda M (2016) Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS 30(8):1313\u20131315. https:\/\/doi.org\/10.1097\/QAD.0000000000001055","journal-title":"AIDS"},{"issue":"6","key":"2508_CR44","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","volume":"32","author":"N Mulligan","year":"2018","unstructured":"Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E, Chakhtoura N, Burchett S, Mirochnick M, Team IPP (2018) Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS 32(6):729\u2013737. https:\/\/doi.org\/10.1097\/QAD.0000000000001755","journal-title":"AIDS"},{"issue":"6","key":"2508_CR45","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1128\/AAC.00173-15","volume":"59","author":"JB Pain","year":"2015","unstructured":"Pain JB, Le MP, Caseris M, Amiel C, Lassel L, Charpentier C, Desnoyer A, Farnoux C, Pialoux G, Descamps D, Peytavin G (2015) Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. Antimicrob Agents Chemother 59(6):3660\u20133662. https:\/\/doi.org\/10.1128\/AAC.00173-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2508_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40262-018-0684-z","volume":"58","author":"R van der Galien","year":"2019","unstructured":"van der Galien R, Ter Heine R, Greupink R, Schalkwijk SJ, van Herwaarden AE, Colbers A, Burger DM (2019) Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps. Clin Pharmacokinet 58(3):309\u2013323. https:\/\/doi.org\/10.1007\/s40262-018-0684-z","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"2508_CR47","doi-asserted-by":"publisher","first-page":"e804","DOI":"10.1016\/S2214-109X(18)30218-3","volume":"6","author":"R Zash","year":"2018","unstructured":"Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Gaolethe T, Petlo C, Lockman S, Holmes LB, Makhema J, Shapiro RL (2018) Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health 6(7):e804\u2013e810. https:\/\/doi.org\/10.1016\/S2214-109X(18)30218-3","journal-title":"Lancet Glob Health"},{"issue":"12","key":"2508_CR48","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/sj.bjc.6600366","volume":"86","author":"ET Waas","year":"2002","unstructured":"Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T (2002) Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 86(12):1876\u20131883. https:\/\/doi.org\/10.1038\/sj.bjc.6600366","journal-title":"Br J Cancer"},{"key":"2508_CR49","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","volume":"152","author":"S Dutta","year":"2016","unstructured":"Dutta S, Sengupta P (2016) Men and mice: relating their ages. Life Sci 152:244\u2013248. https:\/\/doi.org\/10.1016\/j.lfs.2015.10.025","journal-title":"Life Sci"},{"key":"2508_CR50","unstructured":"United States Environmental Protection Agency (US EPA) (2016) Developmental neurotoxicity study guidance. https:\/\/www.epa.gov\/pesticide-science-and-assessing-pesticide-risks\/developmental-neurotoxicity-study-guidance. Accessed December 2018"},{"key":"2508_CR51","unstructured":"Organisation for Economic Co-operation and Development (OECD) (2007) OECD guidelines for the testing of chemicals. Test no. 426: developmental neurotoxicity study. https:\/\/www.oecd-ilibrary.org\/environment\/test-no-426-developmental-neurotoxicity-study_9789264067394-en. Accessed December 2018"},{"key":"2508_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fnint.2013.00009","volume":"7","author":"LM Alba-Ferrara","year":"2013","unstructured":"Alba-Ferrara LM, de Erausquin GA (2013) What does anisotropy measure? Insights from increased and decreased anisotropy in selective fiber tracts in schizophrenia. Front Integr Neurosci 7:9. https:\/\/doi.org\/10.3389\/fnint.2013.00009","journal-title":"Front Integr Neurosci"},{"issue":"3","key":"2508_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/nbm.1145","volume":"20","author":"JK Choi","year":"2007","unstructured":"Choi JK, Dedeoglu A, Jenkins BG (2007) Application of MRS to mouse models of neurodegenerative illness. NMR Biomed 20(3):216\u2013237. https:\/\/doi.org\/10.1002\/nbm.1145","journal-title":"NMR Biomed"},{"issue":"7","key":"2508_CR54","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1097\/j.pain.0000000000001815","volume":"161","author":"C Jung","year":"2020","unstructured":"Jung C, Ichesco E, Ratai EM, Gonzalez RG, Burdo T, Loggia ML, Harris RE, Napadow V (2020) Magnetic resonance imaging of neuroinflammation in chronic pain: a role for astrogliosis? Pain 161(7):1555\u20131564. https:\/\/doi.org\/10.1097\/j.pain.0000000000001815","journal-title":"Pain"},{"issue":"2","key":"2508_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/nbm.1940040203","volume":"4","author":"BL Miller","year":"1991","unstructured":"Miller BL (1991) A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 4(2):47\u201352. https:\/\/doi.org\/10.1002\/nbm.1940040203","journal-title":"NMR Biomed"},{"issue":"13","key":"2508_CR56","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1097\/QAD.0000000000002289","volume":"33","author":"RM Cabrera","year":"2019","unstructured":"Cabrera RM, Souder JP, Steele JW, Yeo L, Tukeman G, Gorelick DA, Finnell RH (2019) The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid. AIDS 33(13):1967\u20131976. https:\/\/doi.org\/10.1097\/QAD.0000000000002289","journal-title":"AIDS"},{"key":"2508_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002741","author":"NC Chandiwana","year":"2020","unstructured":"Chandiwana NC, Chersich M, Venter WF, Akpomiemie G, Hill A, Simmons B, Lockman S, Serenata CM, Fairlie L, Moorhouse MA (2020) Unexpected interactions between dolutegravir and folate: randomised trial evidence from South Africa. AIDS. https:\/\/doi.org\/10.1097\/QAD.0000000000002741","journal-title":"AIDS"},{"issue":"1","key":"2508_CR58","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/QAD.0000000000002407","volume":"34","author":"EH Romach","year":"2020","unstructured":"Romach EH, Stanislaus D, Zamek-Gliszczynski MJ (2020) Letter to the editor re: Cabrera et al., 2019 \u2018The antagonism of folate receptor by dolutegravir developmental toxicity reduction by supplemental folic acid.\u2019 AIDS 34(1):162\u2013163. https:\/\/doi.org\/10.1097\/QAD.0000000000002407","journal-title":"AIDS"},{"issue":"8","key":"2508_CR59","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1124\/dmd.119.087635","volume":"47","author":"MJ Zamek-Gliszczynski","year":"2019","unstructured":"Zamek-Gliszczynski MJ, Zhang X, Mudunuru J, Du Y, Chen JL, Taskar KS, Huang J, Huang Y, Romach EH (2019) Clinical extrapolation of the effects of dolutegravir and other HIV integrase inhibitors on folate transport pathways. Drug Metab Dispos 47(8):890\u2013898. https:\/\/doi.org\/10.1124\/dmd.119.087635","journal-title":"Drug Metab Dispos"},{"issue":"16","key":"2508_CR60","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s00018-019-03171-9","volume":"76","author":"S Chopra","year":"2019","unstructured":"Chopra S, Overall CM, Dufour A (2019) Matrix metalloproteinases in the CNS: interferons get nervous. Cell Mol Life Sci 76(16):3083\u20133095. https:\/\/doi.org\/10.1007\/s00018-019-03171-9","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2508_CR61","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1007\/s12035-018-1273-8","volume":"56","author":"JR Montenegro-Burke","year":"2019","unstructured":"Montenegro-Burke JR, Woldstad CJ, Fang M, Bade AN, McMillan J, Edagwa B, Boska MD, Gendelman HE, Siuzdak G (2019) Nanoformulated antiretroviral therapy attenuates brain metabolic oxidative stress. Mol Neurobiol 56(4):2896\u20132907. https:\/\/doi.org\/10.1007\/s12035-018-1273-8","journal-title":"Mol Neurobiol"},{"key":"2508_CR62","unstructured":"US Food and Drug Administration (FDA) (2021) FDA approves cabenuva and vocabria for the treatment of HIV-1 infection. https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection. Accessed February 27th 2021"},{"issue":"10267","key":"2508_CR63","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, Garcia Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W (2021) Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 396(10267):1994\u20132005. https:\/\/doi.org\/10.1016\/S0140-6736(20)32666-0","journal-title":"Lancet"},{"issue":"4","key":"2508_CR64","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/toxins8040122","volume":"8","author":"N Giebeler","year":"2016","unstructured":"Giebeler N, Zigrino P (2016) A disintegrin and metalloprotease (ADAM): historical overview of their functions. Toxins (Basel) 8(4):122. https:\/\/doi.org\/10.3390\/toxins8040122","journal-title":"Toxins (Basel)"},{"key":"2508_CR65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13059-015-0676-3","volume":"16","author":"R Kelwick","year":"2015","unstructured":"Kelwick R, Desanlis I, Wheeler GN, Edwards DR (2015) The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. Genome Biol 16:113. https:\/\/doi.org\/10.1186\/s13059-015-0676-3","journal-title":"Genome Biol"},{"issue":"2","key":"2508_CR66","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T (2011) In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55(2):813\u2013821. https:\/\/doi.org\/10.1128\/AAC.01209-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2508_CR67","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2352-3018(20)30268-X","volume":"8","author":"GFM Pereira","year":"2021","unstructured":"Pereira GFM, Kim A, Jalil EM, Fernandes Fonseca F, Shepherd BE, Veloso VG, Rick F, Ribeiro R, Pimenta MC, Beber A, Correa RG, Lima R, Maruri F, McGowan CC, Schwartz Benzaken A, Grinsztejn B, Castilho JL, National Cohort Study of D, Pregnancy Outcomes in B (2021) Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV 8(1):e33\u2013e41. https:\/\/doi.org\/10.1016\/S2352-3018(20)30268-X","journal-title":"Lancet HIV"},{"issue":"5","key":"2508_CR68","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s13365-020-00870-z","volume":"26","author":"P Amusan","year":"2020","unstructured":"Amusan P, Power C, Gill MJ, Gomez D, Johnson E, Rubin LH, Fujiwara E (2020) Lifetime antiretroviral exposure and neurocognitive impairment in HIV. J Neurovirol 26(5):743\u2013753. https:\/\/doi.org\/10.1007\/s13365-020-00870-z","journal-title":"J Neurovirol"},{"issue":"1","key":"2508_CR69","first-page":"14","volume":"20","author":"JC Yombi","year":"2018","unstructured":"Yombi JC (2018) Dolutegravir neuropsychiatric adverse events: specific drug effect or class effect. AIDS Rev 20(1):14\u201326","journal-title":"AIDS Rev"},{"issue":"7","key":"2508_CR70","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/ciz407","volume":"70","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, Koethe JR, Sterling TR (2020) Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis 70(7):1267\u20131274. https:\/\/doi.org\/10.1093\/cid\/ciz407","journal-title":"Clin Infect Dis"},{"key":"2508_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100615","volume":"29\u201330","author":"EC Caniglia","year":"2020","unstructured":"Caniglia EC, Shapiro R, Diseko M, Wylie BJ, Zera C, Davey S, Isaacson A, Mayondi G, Mabuta J, Luckett R, Makhema J, Mmalane M, Lockman S, Zash R (2020) Weight gain during pregnancy among women initiating dolutegravir in Botswana. EClinicalMedicine 29\u201330:100615. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100615","journal-title":"EClinicalMedicine"},{"issue":"9","key":"2508_CR72","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"C Kouanfack","year":"2019","unstructured":"Group NAS, Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E (2019) Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med 381(9):816\u2013826. https:\/\/doi.org\/10.1056\/NEJMoa1904340","journal-title":"N Engl J Med"},{"issue":"9","key":"2508_CR73","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A (2019) Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 381(9):803\u2013815. https:\/\/doi.org\/10.1056\/NEJMoa1902824","journal-title":"N Engl J Med"},{"issue":"16","key":"2508_CR74","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00018-019-03180-8","volume":"76","author":"A Beroun","year":"2019","unstructured":"Beroun A, Mitra S, Michaluk P, Pijet B, Stefaniuk M, Kaczmarek L (2019) MMPs in learning and memory and neuropsychiatric disorders. Cell Mol Life Sci 76(16):3207\u20133228. https:\/\/doi.org\/10.1007\/s00018-019-03180-8","journal-title":"Cell Mol Life Sci"},{"key":"2508_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa259","author":"J Gorwood","year":"2020","unstructured":"Gorwood J, Bourgeois C, Pourcher V, Pourcher G, Charlotte F, Mantecon M, Rose C, Morichon R, Atlan M, Le Grand R, Desjardins D, Katlama C, Feve B, Lambotte O, Capeau J, Bereziat V, Lagathu C (2020) The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa259","journal-title":"Clin Infect Dis"},{"key":"2508_CR76","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/VHRM.S103877","volume":"12","author":"J Jaoude","year":"2016","unstructured":"Jaoude J, Koh Y (2016) Matrix metalloproteinases in exercise and obesity. Vasc Health Risk Manag 12:287\u2013295. https:\/\/doi.org\/10.2147\/VHRM.S103877","journal-title":"Vasc Health Risk Manag"},{"key":"2508_CR77","doi-asserted-by":"publisher","unstructured":"Li X, Zhao Y, Chen C, Yang L, Lee HH, Wang Z, Zhang N, Kolonin MG, An Z, Ge X, Scherer PE, Sun K (2020) Critical role of matrix metalloproteinase 14 in adipose tissue remodeling during obesity. Mol Cell Biol 40 (8). https:\/\/doi.org\/10.1128\/MCB.00564-19","DOI":"10.1128\/MCB.00564-19"},{"key":"2508_CR78","doi-asserted-by":"publisher","unstructured":"Ruiz-Ojeda FJ, Mendez-Gutierrez A, Aguilera CM, Plaza-Diaz J (2019) Extracellular matrix remodeling of adipose tissue in obesity and metabolic diseases. Int J Mol Sci 20 (19). https:\/\/doi.org\/10.3390\/ijms20194888","DOI":"10.3390\/ijms20194888"},{"issue":"23","key":"2508_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399403006628","volume":"5","author":"MA Lafleur","year":"2003","unstructured":"Lafleur MA, Handsley MM, Edwards DR (2003) Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 5(23):1\u201339. https:\/\/doi.org\/10.1017\/S1462399403006628","journal-title":"Expert Rev Mol Med"},{"issue":"2","key":"2508_CR80","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bcp.2007.07.004","volume":"75","author":"JD Raffetto","year":"2008","unstructured":"Raffetto JD, Khalil RA (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75(2):346\u2013359. https:\/\/doi.org\/10.1016\/j.bcp.2007.07.004","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"2508_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30231-9","volume":"7","author":"H The Lancet","year":"2020","unstructured":"The Lancet H (2020) End resistance to dolutegravir roll-out. Lancet HIV 7(9):e593. https:\/\/doi.org\/10.1016\/S2352-3018(20)30231-9","journal-title":"Lancet HIV"},{"key":"2508_CR82","unstructured":"World Health Organization (2018) Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir\/lamivudine\/dolutegravir (TLD): Briefing note. http:\/\/www.who.int\/hiv\/pub\/arv\/DTG-TLD-arv_briefing_2018.pdf"},{"key":"2508_CR83","unstructured":"The Joint United Nations Programme on HIV\/AIDS (UNAIDS) (2019) Global HIV & AIDS statistics\u20142020"},{"issue":"9","key":"2508_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30270-X","volume":"6","author":"H The Lancet","year":"2019","unstructured":"The Lancet H (2019) A lesson to learn from dolutegravir roll-out. Lancet HIV 6(9):e559. https:\/\/doi.org\/10.1016\/S2352-3018(19)30270-X","journal-title":"Lancet HIV"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02508-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-021-02508-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02508-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T20:18:26Z","timestamp":1637180306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-021-02508-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2508"],"URL":"https:\/\/doi.org\/10.1007\/s12035-021-02508-5","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee (IACUC) in accordance with the standards incorporated in the Guide for the Care and Use of Laboratory Animals (National Research Council of the National Academies, 2011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Drs. Benson Edagwa and Howard E. Gendelman are co-founders of Exavir Therapeutics, Inc., a biotechnology company focused on the development of long-acting antiretroviral medicines. The remaining authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}